Intravitreal triamcinolone acetonide for patients with macular edema due to branch retinal vein occlusion

Kaohsiung Journal of Medical Sciences

Volumn 22, Issue 7, 2006, Pages 321-330

  Cheng, Kai Chun ^a   Wu, Wen Chuan ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Branch retinal vein occlusion; Intravitreal triamcinolone acetonide; Macular edema

Indexed keywords

POVIDONE IODINE; TOBRAMYCIN; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; OPTICAL COHERENCE TOMOGRAPHY; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; RETINA MACULA EDEMA; RETINA VEIN OCCLUSION; TREATMENT OUTCOME; VISUAL ACUITY;

EID: 33746891928     PISSN: 02575655     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1607-551x(09)70318-3     Document Type: Article

References (52)

1. Branch Vein Occlusion Study Group. Argon laser scatter photocoagulation for prevention of neovascularization and vitreous hemorrhage in branch vein occlusion. Arch Ophthalmol 1986;104:34-41.
2. Jensen VA. Clinical studies of tributary thrombosis in central retinal vein. Acta Ophthalmol Suppl 1936;10:1-193.
3. Duker JS, Brown GC. Anterior location of the crossing artery in branch retinal vein obstruction. Arch Ophthalmol 1989;107:998-1000.
4. Weinberg D, Dodwell DG, Fern SA. Anatomy of arteriovenous crossings in branch retinal vein occlusion. Am J Ophthalmol 1990;109:298-302.
5. Christoffersen NL, Larsen M. Pathophysiology and hemodynamics of branch retinal vein occlusion. Ophthalmology 1999;106:2054-62.
6. Becker B, Post LT Jr. Retinal vein occlusion. Clinical and experimental observations. Am J Ophthalmol 1951;34:677-86.
7. Blankenship GW, Okun E. Retinal tributary vein occlusion. History and management by photocoagulation. Arch Ophthalmol 1973;89:363-8.
8. Gutman FA, Zegarra H. The natural course of temporal retinal branch vein occlusion. Trans Am Acad Ophthalmol Otolaryngol 1974;78:OP178-92.
9. Fekrat S, Goldberg MF, Finkelstein D. Laser-induced chorioretinal venous anastomosis for nonischemic central or branch retinal vein occlusion. Arch Ophthalmol 1998;116:43-52.
10. Finkelstein D. Ischemic macular edema: recognition and favorable natural history in branch vein occlusion. Arch Ophthalmol 1992;110:1427-34.
11. Finkelstein D, Clarkson JG and The Branch Vein Occlusion Study Group. Branch and Central Retinal Vein Occlusions. Focal Points 1987: Clinical Modules for Ophthalmologists 5 (module 12), no 3, American Academy of Ophthalmology.
12. Glitinan FA, Zegarra H. Macular edema secondary to occlusion of the retinal veins. Surv Ophthalmol 1984;28:462-70.
13. Hattenbach LO, Steinkamp G, Scharrer I, et al. Fibrinolytic therapy with low-dose recombinant tissue plasminogen activator in retinal vein occlusion. Ophthalmologica 1998;212:394-8.
14. Opremcak EM, Bruce RA. Surgical decompression of branch retinal vein occlusion via arteriovenous crossing sheathotomy: a prospective review of 15 cases. Retina 1999;19:1-5.
15. Cahill MT, Kaiser PK, Sears JE, et al. The effect of arteriovenous sheathotomy on cystoid macular oedema secondary to branch retinal vein occlusion. Br J Ophthalmol 2003;87:1329-32.
16. Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. Am J Ophthalmol 1984;98:271-82.
17. Antcliff RJ, Spalton DJ, Stanford MR, et al. Intravitreal triamcinolone for uveitic cystoid macular edema: an optical coherence tomography study. Ophthalmology 2001;108:765-72.
18. Jonas JB, Sofker A. Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001;132:425-7.
19. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002;109:920-7.
20. Jonas JB, Sofker A. Intravitreal injection of crystalline cortisone as adjunctive treatment of proliferative diabetic retinopathy. Am J Ophthalmol 2001;131:468-71.
21. Andrade RE, Muccioli C, Farah ME, et al. Intravitreal triamcinolone in the treatment of serous retinal detachment in Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 2004;137:572-4.
22. Jonas JB. Intravitreal triamcinolone acetonide for treatment of sympathetic ophthalmia. Am J Ophthalmol 2004;137:367-8.
23. Greenberg PB, Martidis A, Rogers AH, et al. Intravitreal triamcinolone acetonide for macular oedema due to central retinal vein occlusion. Br J Ophthalmol 2002;86:247-8.
24. Al-Haddad CE, Jurdi FA, Bashshur ZF. Intravitreal triamcinolone acetonide for the management of diabetic papillopathy. Am J Ophthalmol 2004;137:1151-3.
25. Jonas JB, Akkoyun I, Kamppeter B, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide. Eye 2005;19:65-71.
26. Lee H, Shah GK. Intravitreal triamcinolone as primary treatment of cystoid macular edema secondary to branch retinal vein occlusion. Retina 2005;25:551-5.
27. Cekic O, Chang S, Tseng JJ, et al. Intravitreal triamcinolone injection for treatment of macular edema secondary to branch retinal vein occlusion. Retina 2005;25:851-5.
28. Antonetti DA, Wolpert EB, DeMaio L, et al. Hydrocortisone decrease retinal endothelial cell water and solute flux coincident with increased content and decreased phosphorylation of occludin. J Neurochem 2002;80:667-77.
29. Kompella UB, Bandi N, Ayalasomayajula SP. Sub-conjunctival nano- and microparticles sustain retinal delivery of budesonide, a corticosteroid capable of inhibiting VEGF expression. Invest Ophthalmol Vis Sci 2003;44:1192-201.
30. Fischer S, Renz D, Schaper W, et al. In vitro effects of dexamethasone on hypoxia-induced hyperpermeability and expression of vascular endothelial growth factor. Eur J Pharmacol 2001;411:231-43.
31. Tamura H, Miyamoto K, Kiryu J, et al. Intravitreal injection of corticosteroid attenuates leukostasis and vascular leakage in experimental diabetic retina. Invest Ophthalmol Vis Sci 2005;46:1440-4.
32. Salinas-Alaman A, Garcia-Layana A, Sadaba-Echarri LM, et al. Branch retinal vein occlusion treated by intravitreal triamcinolone. Arch Soc Esp Oftalmol 2005;80:463-5.
33. Young S, Larkin G, Branley M, et al. Safety and efficacy of intravitreal triamcinolone for cystoid macular oedema in uveitis. Clin Exp Ophthalmol 2001;29:2-6.
34. McCuen II BW, Bessler M, Tano Y, et al. The lack of toxicity of intravitreally administered triamcinolone acetonide. Am J Ophthalmol 1981;91:785-8.
35. Hida T, Chandler D, Arena JE, et al. Experimental and clinical observations of the intraocular toxicity of commercial corticosteroid preparations. Am J Ophthalmol 1986;101:190-5.
36. Kwak HW, D'Amico DJ. Evaluation of the retinal toxicity and pharmacokinetics of dexamethasone after intravitreal injection. Arch Ophthalmol 1992;110:259-66.
37. Kivilcim M, Peyman GA, EI-Dessouky ES, et al. Retinal toxicity of triamcinolone acetonide in silicone-filled eyes. Ophthalmic Surg Lasers 2000;31:474-8.
38. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002;109:920-7.
39. Wingate RJ, Beaumont PE. Intravitreal triamcinolone and elevated intraocular pressure. Aust N Z J Ophthalmol 1999;27:431-2.
40. Jonas JB, Kreissig I, Degenring R. Intraocular pressure after intravitreal injection of triamcinolone acetonide. Br J Ophthalmol 2003;87:24-7.
41. Bakri SJ, Beer PM. The effect of intravitreal triamcinolone acetonide on intraocular pressure. Ophthalmic Surg Lasers Imaging 2003;34:386-90.
42. Challa JK, Gillies MC, Penfold PL, et al. Exudative macular degeneration and intravitreal triamcinolone: 18-month follow-up. Aust N Z J Ophthalmol 1998;26:277-81.
43. Danis RP, Ciulla TA, Pratt LM, et al. Intravitreal triamcinolone acetonide in exudative age-related macular degeneration. Retina 2000;20:244-50.
44. Jonas JB, Kreissig I, Sofker A, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2003;121:57-61.
45. Park CH, Jaffe GJ, Fejrat S. Intravitreal triamcinolone acetonide in eyes with cystoid macular oedema associated with central retinal vein occlusion. Am J Ophthalmol 2003;136:419-25.
46. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular oedema. Ophthalmology 2002;109:920-7.
47. Moshfeghi DM, Kaiser PK, Scott IU, et al. Acute endophthalmitis following intravitreal triamcinolone acetonide injection. Am J Ophthalmol 2003;136:791-6.
48. Nelson ML, Tennant MTS, Sivalingam A, et al. Infectious and presumed non-infectious endophthalmitis after intravitreal triamcinolone acetonide injection. Retina 2003;23:686-91.
49. Moshfeghi AA, Scott IU, Flynn HW, et al. Pseudohypopyon after intravitreal triamcinolone acetonide injection for cystoid macular edema. Am J Ophthalmol 2004;138:489-92.
50. Roth DB, Chieh J, Spirn MJ, et al. Non-infectious endophthalmitis associated with intravitreal triamcinolone injection. Arch Ophthalmol 2003;121:1279-82.
51. Chiu YT, Tsai YY, Lin JM. Noninfectious hypopyon after intravitreal triamcinolone acetonide injection for central retinal vein occlusion: a case report. Kaohsiung J Med Sci 2005;21:466-9.
52. Sutter FKP, Gillies MC. Pseudoendophthalmitis after intravitreal injection of triamcinolone. Br J Ophthalmol 2003;87:972-4.